Verastem down on duvelisib update at ASH

Verastem Inc. (NASDAQ:VSTM) fell $0.73 (17%) to $3.60 on Monday after reporting additional data from the Phase III DUO trial evaluating duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented Sunday at the American Society of Hematology meeting in Atlanta.

At ASH, Verastem said duvelisib missed the secondary endpoint of improving overall survival (OS) vs. Arzerra ofatumumab (HR=0.99, p=0.4807). The company said the miss was "likely due to other available therapies following progression." Patients who progressed in DUO had the option to enroll in a crossover study to receive the opposite treatment...